NCT04850053 · RECRUITING
Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis
This study tests a new blood-based detection device that measures abnormal protein clumps — amyloid-beta and tau seeds — to see how accurately it can identify Alzheimer's disease. Researchers will compare results from people with AD against healthy controls and people with other dementias. It has no assigned phase, meaning it is a diagnostic accuracy study rather than a treatment trial, and no intervention is being given to participants.
You may qualify if
- Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. As for non-AD dementia, the McKeith criteria are used for DLB,the revised diagnostic criteria proposed by the International behavioral variant (bvFTD) Criteria Consortium for bvFTD,the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.
You're excluded if
- Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-23